Levetiracetam-induced parkinsonism in a Huntington disease patient.

Abstract

The authors present a man with Huntington disease who was treated with levetiracetam (Keppra) in an effort to reduce chorea. Chorea was markedly reduced, but the patient developed parkinsonism and lethargy after 6 weeks of treatment. Symptoms consisted of resting tremor, rigidity, increased dystonia, and gait difficulty. Side effects from levetiracetam resolved completely within 7 days of levetiracetam discontinuation, and chorea returned to baseline.

• Authors: Theresa A Zesiewicz, Juan Sanchez-Ramos, Kelly L Sullivan, Robert A Hauser
• Journal: Clinical neuropharmacology (Clin Neuropharmacol) 2005 Jul-Aug Vol. 28 Issue 4 Pg. 188-90 ISSN: 0362-5664 [Print] United States
• PMID: 16062099 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antipsychotic Agents
• Nootropic Agents
• Levetiracetam
• Piracetam

Topics

• Antipsychotic Agents (adverse effects, therapeutic use)
• Dementia (drug therapy, etiology)
• Gait Disorders, Neurologic (chemically induced)
• Humans
• Huntington Disease (complications, drug therapy)
• Levetiracetam
• Male
• Middle Aged
• Muscle Rigidity (chemically induced)
• Neuropsychological Tests
• Nootropic Agents (adverse effects, therapeutic use)
• Parkinson Disease, Secondary (chemically induced)
• Piracetam (adverse effects, analogs & derivatives, therapeutic use)
• Tremor (chemically induced)